Biologic medicines and biosimilars in the Australian landscape – the challenges and the opportunities

Discussion Paper: Allens is engaging with stakeholders on the challenges and opportunities presented by biosimilars. As part of this engagement, a multidisciplinary team at Allens have prepared a summary of relevant issues for discussion and comment.

Download the discussion paper


Sector leader

Jeremy Low

Jeremy Low
+61 2 9230 4041
Email Jeremy

View CV

Business development manager

Jack Edmonds
+61 2 9230 4550
Email Jack

The healthcare sector faces great change and opportunities in delivering patient wellbeing.

Allens draws on its many decades working with the healthcare industry to deliver insight and innovative advice across every stage of the product lifecycle.

Our team's deep understanding of the healthcare sector is augmented by an extensive background in life sciences, with many members of our team holding doctorates in advanced sciences and having worked in pharmaceutical and biomedical research around the world.

Market opportunities

Rapid innovation in personal health technology and personalised medicine is creating new ways to assist patients along with new challenges for regulators and industry participants. We are at the forefront of horizon issues in eHealth.

The pharmaceuticals and biotech industry is also adapting to deal with significant challenges, such as the patent cliff and the emergence of biosimilars.

In Australia, as in other developed countries, private sector investment is required to meet the future healthcare needs of Australia's ageing population. At the same time, in Asia, an emerging middle class is driving an increase in demand for private healthcare services. As established international businesses, Australian private hospital operators are well placed to capitalise on this growth in demand.

Leading expertise and industry insight

We help leading businesses across healthcare services, pharmaceuticals and medical devices to navigate the rapidly changing regulatory landscape and manage transactions, investments and disputes.

Given the current market climate and strong demand for healthcare assets, we are advising on industry consolidation and strategic realignment including asset-swap, carve-out and spin-out transactions. Allens is proud to have advised on the largest and most complex M&A transactions in the healthcare sector. Our competition and regulatory experts have an unbeatable track record.

As payers seek to contain growing healthcare costs, pricing and reimbursement are crucial issues. We maintain a network of specialist healthcare regulatory and compliance lawyers in key global jurisdictions to assist our clients deal with local legislative regimes – wherever they do business.

Delivering a comprehensive patent offering to clients, Allens' integrated Patent & Trade Mark Attorneys firm are market leaders in the healthcare sector.

As Australia's leading patent disputes firm, we have an experienced team of intellectual property litigators with excellent credentials in commercial negotiations and a track record second to none in high-stakes patent litigation.

Healthcare clients also benefit from our specialist expertise in class actions, employment, product liability, technology, financing, infrastructure, property and tax.